Goldman Sachs Maintains Buy on Agilon Health, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Jamie Perse maintains a Buy rating on Agilon Health (NYSE:AGL) but has lowered the price target from $25 to $22.
November 09, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Agilon Health but lowers the price target from $25 to $22.
The news is directly related to Agilon Health (AGL). While the maintained Buy rating is positive, the lowered price target might indicate a potential downside, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100